VOR Vor Biopharma Inc.
Listings ·
Vor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with.
Vor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027.
Vor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $321.5 million | $93.3 million |
| Net income (loss) | -$696.0 million | -$116.9 million |
| Cash from operations | -$142.7 million | -$99.7 million |
| Cash and equivalents | $396.5 million | $81.9 million |
| Short-term investments | $58.7 million | $10.0 million |
Vor Biopharma Inc. trades under the ticker VOR on NASDAQ.
Vor Biopharma Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Vor Biopharma Inc. is 1817229. Its filings are on SEC EDGAR.
59,162,294 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Vor Biopharma Inc. under United States.
Our directory classifies Vor Biopharma Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Vor Biopharma Inc. is US9290332074.
aibio.space lists Vor Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Vor Biopharma Inc. reported a net loss of $696.0 million for the fiscal year ended Dec 31, 2025, and used $142.7 million of cash in operations, per its annual report to the SEC.
$321.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$481.6 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.
Our latest story on Vor Biopharma, dated Jul 10, 2025: "Vor Bio names Sandy Mahatme CFO and grants 13,882,750 inducement RSUs". Vor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with. Source.
Our latest financing story, dated Jun 26, 2025: "Vor Bio licenses telitacicept from RemeGen for $45 million plus $80 million in warrants". Vor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027. Source.
From our story of Jun 26, 2025: It also names Vor Bio's ability to continue as a going concern. Source.
Our latest distress story, dated May 8, 2025: "Vor Biopharma winds down clinical operations, cuts 147 jobs and explores strategic alternatives". Vor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause. Source.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,3.02,5.02,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio